menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Modernizing Drug Evaluation To Bring Faster Translation

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    While new science continues to evolve the development of drugs and cures, the scientific principals we use to evaluate the drugs is arguably obsolete. Host Dr. Bruce Bloom is joined in this segment by Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, and Dr. Scott Gottlieb, a practicing physician and resident fellow at the American Enterprise Institute (AEI). Listen in to learn how clinical trial models might be changed to better evaluate the success of new drugs that target subsets of the population with certain cancers, and expedite translatable cures.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    While new science continues to evolve the development of drugs and cures, the scientific principals we use to evaluate the drugs is arguably obsolete. Host Dr. Bruce Bloom is joined in this segment by Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, and Dr. Scott Gottlieb, a practicing physician and resident fellow at the American Enterprise Institute (AEI). Listen in to learn how clinical trial models might be changed to better evaluate the success of new drugs that target subsets of the population with certain cancers, and expedite translatable cures.

Facebook Comments

Schedule29 Mar 2024